S5-04.1 – Appreciating the Disease Burden of MASLD
Zobair Younossi discusses the disease burden of MASLD as characterized in his recent publication “Understanding the Burden of Fatty Liver Disease: Time for Action”
March 2, 2024
Zobair Younossi discusses the disease burden of MASLD as characterized in his recent publication “Understanding the Burden of Fatty Liver Disease: Time for Action”
Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.
Patient advocates Neeraj Mistry of the Fatty Liver Foundation and Jenn Leigh Jones of the Society for Sober Liver Survival join Louise Campbell and Roger Green to discuss the merging of their organizations and the impact of the new nomenclature on how patients might look at their disease.
Dr. Tim Jobson of Predictive Health Intelligence joins Roger Green in our continuing TLM2023 coverage. Tim and Roger discussing PHI’s work in data-based identification of patients who are not receiving needed treatment and how this pertains to the vast global need for MASLD screening.
Dr. Zobair Younossi joins Roger Green to kick off our review coverage of TLM 2023. Dr. Younossi discusses the studies he presented at the meeting and discusses other work related to patient quality-of-life, economics of screening and treatment, and how stigma affects both patients and providers.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment features ideas around how health care systems can improve and important lessons learned from the COVID pandemic.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment introduces three important questions that the group aims to answer throughout the wider episode.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
What do liver nursing KOLs see as the largest, most important changes they can hope for 2-3 years from now?